Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Advagene Biopharma CoROCO:6709 -4.00%34 Buyback Yield % is 0.00 as of Jul. 25, 2026. GuruFocus rates ROCO:6709 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 738 Biotechnology companies, Advagene Biopharma Co ranks worse than 135501.22% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Advagene Biopharma Co Buyback Yield % Related Terms
Advagene Biopharma Co Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Advagene Biopharma Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6709 vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Advagene Biopharma Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advagene Biopharma Co Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Advagene Biopharma Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Advagene Biopharma Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advagene Biopharma Co (ROCO:6709) has a Buyback Yield % of 0.00 as of Jul. 25, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Advagene Biopharma Co and its competitors. According to the industry distribution chart, Advagene Biopharma Co ranks #999999 out of 738 companies in the Biotechnology industry.
Is Advagene Biopharma Co's Buyback Yield % too high?
Advagene Biopharma Co's current Buyback Yield % is 0.00. Based on the distribution chart, Advagene Biopharma Co ranks #999999 out of 738 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Advagene Biopharma Co has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Advagene Biopharma Co's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Advagene Biopharma Co ranks #999999 out of 738 companies for Buyback Yield %. This places Advagene Biopharma Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Advagene Biopharma Co and its competitors. Advagene Biopharma Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advagene Biopharma Co stock overvalued right now?
Advagene Biopharma Co (ROCO:6709) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Advagene Biopharma Co's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Advagene Biopharma Co (ROCO:6709), the current Buyback Yield % is 0.00 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based biotechnology company. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray seasonal flu vaccine, nasal spray COVID-19 vaccine, Immunotherapy for COVID-19, Respiratory Allergy Immunotherapy - Allergic Rhinitis and Asthma ,and other vaccines.
34GF Score
Get the complete analysis for ROCO:6709
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6709 has been successfully added to your 
